About REXAHN

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing the next generation of targeted therapeutics for the treatment of cancer.
Rexahn's clinical development programs target specific proteins that are selectively localized in human cancer cells and not in healthy tissues resulting in increased efficacy and reduced toxicity.


News

Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage


Rexahn Reports First Quarter 2018 Financial Results


More


Portfolio